“I am very pleased to welcome Raheleh to Orexo at an important stage in our development. She brings deep experience from the pharmaceutical industry from both business development and international commercial roles. In her career she has worked with a broad range of molecules, including vaccines,” said Nikolaj Sørensen, President and CEO. “Raheleh has also a strong track record of establishing and maintaining valuable partnerships. Her expertise will be instrumental as we intensify our focus on realizing the full potential of our proprietary AmorphOX technology.”

Raheleh Nassaji

Raheleh Nassaji is a biopharma executive with close to 20 years of global experience across big pharma and biotech. She brings a unique combination of scientific expertise, business development, and strategic partnerships gained through senior roles at companies across various stages of development, including Hansa Biopharma and Pfizer. Her background also includes late-stage product launches and commercialization as well as early-stage strategy and clinical development planning. This breadth of expertise enables her to bridge scientific innovation with commercial execution and strategic growth.

“I am excited to join Orexo and contribute to driving its next phase of growth. Orexo combines a strong history of innovation and value-creating partnerships with a differentiated technology platform and a promising pipeline. I look forward to working with the team to expand strategic partnerships, advance opportunities around AmorphOX, and create long-term value through collaborations that accelerate the development and broaden the reach of Orexo´s technologies and products,” says Raheleh Nassaji, SVP Business Development.